How Long Does Prior Authorization Take for Wegovy? What You Need to Know

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

For most people the legal answer is days, not months — and it depends entirely on what kind of plan you have. If you are covered by an employer-sponsored group health plan, federal claims regulations give the plan no more than 15 days to decide a non-urgent request for care that requires approval in advance, with one permitted 15-day extension, and no more than 72 hours for an urgent care claim. If you are in a Medicare Advantage plan, Medicaid or CHIP managed care, or a Qualified Health Plan on a federally facilitated exchange, a CMS rule that took effect January 1, 2026 requires prior authorization decisions within seven calendar days for standard requests and 72 hours for expedited ones. Those are ceilings, not averages. What stretches a Wegovy prior authorization from a week into a month is rarely the clock the plan is held to — it is incomplete documentation, the wrong indication on the request, and the appeal cycle after a denial.

The Deadlines Your Plan Is Actually Held To

Employer group health plans are governed by the Department of Labor's claims procedure regulation at 29 CFR 2560.503-1. For a pre-service claim — the category a prior authorization falls into — notification of the plan's benefit determination must come "within a reasonable period of time appropriate to the medical circumstances, but not later than 15 days after receipt of the claim." That period may be "extended one time by the plan for up to 15 days" where the plan administrator determines an extension is necessary. For urgent care claims, the plan must notify the claimant "as soon as possible, taking into account the medical exigencies, but not later than 72 hours after receipt of the claim."

Government-sponsored coverage is now on a tighter schedule. Under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), impacted payers must send prior authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests. Beginning in 2026, those payers must also provide a specific reason for a denial regardless of how the request was submitted. CMS finalized these policies with a compliance date starting January 1, 2026; the related Prior Authorization API requirement follows on January 1, 2027. The rule reaches Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care entities, and QHP issuers on the federally facilitated exchanges.

Why Wegovy Requests Get Complicated

Wegovy now carries an unusually broad label for a weight-management product, and prior authorization criteria are usually written against one specific indication rather than the drug as a whole. Per the Wegovy prescribing information, the injection is indicated, with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; for weight reduction in adults and pediatric patients aged 12 years and older with obesity; for weight reduction in adults with overweight plus at least one weight-related comorbidity; and to treat noncirrhotic MASH with moderate to advanced liver fibrosis in adults. Wegovy tablets are indicated for cardiovascular event risk reduction and for weight reduction in adults with obesity or overweight.

Those are four different clinical stories with four different sets of supporting documentation. A cardiovascular risk-reduction request needs evidence of established cardiovascular disease; a weight-reduction request needs body mass index and, for overweight, a documented comorbidity; a MASH request needs a fibrosis stage. Submitting a weight-reduction request when the patient's coverage extends only to the cardiovascular indication is one of the most common reasons a request bounces.

Where the Time Actually Goes

The regulatory clock generally starts when the plan receives the request — which means a week spent chasing chart notes, weight history, prior therapy documentation, or a comorbidity diagnosis before submission is a week nobody is counting. The DOL regulation does account for procedurally deficient filings: where a claimant fails to follow the plan's procedures for a pre-service claim, notification of that failure must come "as soon as possible, but not later than 5 days (24 hours in the case of a failure to file a claim involving urgent care) following the failure."

Step therapy adds another layer. Many plans require documented trial and failure of specified alternatives first, and assembling that history from multiple prescribers takes real time. None of it is captured in the "how long does prior authorization take" number, which is why patient-reported waits routinely exceed the regulatory maximums even when the payer is fully compliant.

Medicare Is Its Own Category

For Medicare Part D the constraint is statutory rather than administrative. Section 1927(d)(2) of the Social Security Act permits exclusion of "agents when used for anorexia, weight loss, or weight gain," which is the basis of Part D's longstanding treatment of weight-loss medications, as described in the HHS ASPE issue brief on Medicare coverage of anti-obesity medications. After Wegovy received its cardiovascular risk-reduction indication in March 2024, CMS issued guidance to plans, and Part D enrollees gained access for that combination of conditions.

There is now a second route. CMS has launched the Medicare GLP-1 Bridge, a short-term demonstration providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026 and December 31, 2027 at a $50 copay. CMS states the demonstration operates outside the Part D benefit's coverage and payment flow, that the Part D deductible does not apply, that the copay does not count toward true out-of-pocket costs, and that no low-income subsidy is provided. Ask your plan whether you qualify — it is a different pathway from a standard Part D prior authorization.

If You Are Denied

A denial is not the end of the process, and as of January 1, 2026 impacted payers must tell you specifically why. That specificity is useful: most denials turn on a missing data element rather than a judgment that the medication is inappropriate. Read the reason, give it to your prescriber's office, and ask whether the gap can be closed with documentation already in your chart.

Appeals have their own regulated timelines, and expedited review exists for situations where the standard timeframe would jeopardize your health. Your prescriber, not you, is usually the one who can characterize a request as urgent — and that characterization is what moves a decision from seven days to 72 hours.

What Not to Do While You Wait

Do not change how you take a medication you are already on, and do not fill gaps with product from an unverified source. The FDA has warned in its statement on unapproved GLP-1 drugs used for weight loss about companies illegally selling unapproved products containing semaglutide or tirzepatide falsely labeled "for research purposes" or "not for human consumption," and notes that semaglutide salt forms are different active ingredients from those used in approved drugs.

If the wait is untenable, a self-pay pathway through a licensed pharmacy on a patient-specific prescription is a legitimate option to discuss with a clinician — with the honest caveat that compounded preparations are not FDA-approved finished products. Any question about how a specific product should be handled belongs to the pharmacy label and your prescriber.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How long can my insurer legally take to decide a Wegovy prior authorization?

For an employer group health plan, federal claims rules require notification within 15 days of a non-urgent pre-service claim, with one permitted 15-day extension, and within 72 hours for an urgent care claim. For Medicare Advantage, Medicaid and CHIP managed care, and exchange plans covered by the CMS final rule, decisions are due within seven calendar days for standard requests and 72 hours for expedited requests as of January 1, 2026.

Why do people report waiting a month or more?

The regulatory clock generally starts when the plan receives a complete request. Time spent gathering chart notes, weight history, comorbidity documentation, or step-therapy records before submission is not counted, and a denial followed by resubmission or appeal restarts much of the process. Federal rules do require a plan to notify a claimant of a procedural filing failure within five days, or 24 hours for urgent care claims.

Does the indication on my request change the outcome?

Frequently, yes. Wegovy carries several distinct indications — cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, weight reduction in adults and patients 12 and older with obesity, weight reduction in adults with overweight plus a weight-related comorbidity, and noncirrhotic MASH with moderate to advanced fibrosis. Plans usually write criteria against one indication, so the documentation must match the one being claimed.

Does Medicare cover Wegovy?

Section 1927(d)(2) of the Social Security Act permits exclusion of agents used for weight loss, which shaped Part D's historical position. After Wegovy's March 2024 cardiovascular indication, CMS issued guidance and Part D enrollees gained access for that combination of conditions. Separately, CMS is running the Medicare GLP-1 Bridge demonstration from July 1, 2026 through December 31, 2027, with a $50 copay for eligible beneficiaries.

What should I do if my prior authorization is denied?

Read the stated reason — as of January 1, 2026, impacted payers must give a specific reason for a denial regardless of how the request was submitted. Most denials reflect a missing data element rather than a clinical judgment. Share the reason with your prescriber's office, ask whether the gap can be closed from your existing chart, and ask whether an expedited appeal is appropriate for your situation.

Medical and Editorial Standards

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.